Nadine Tung

26PUBLICATIONS
202CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 26, 2026
Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Feb 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.

Adriana I Apostol, Jacek Gronwald, Cezary Cybulski

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Oct 02, 2024
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.

Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek

|Jul 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Adrienne G Waks, Emily L Chen, Noah Graham

Pageof 5

Frequent Collaborators

9 joint publications

Eric P Winer

6 joint publications

Sara M Tolaney

6 joint publications

Antonio C Wolff

6 joint publications

Ian Krop